Consensus Report Urges Increased Support for the Metastatic Breast Cancer Community

Publication
Article
OncologyONCOLOGY Vol 22 No 11
Volume 22
Issue 11

The Metastatic Breast Cancer Advocacy Working Group, a cooperative of patient advocates from seven countries, released a consensus report urging other advocacy groups, health-care corporations and professionals, government, academia, community/religious organizations, and all other relevant breast cancer stakeholders worldwide to take action on three priority areas for women living with metastatic breast cancer (MBC)

The Metastatic Breast Cancer Advocacy Working Group, a cooperative of patient advocates from seven countries, released a consensus report urging other advocacy groups, health-care corporations and professionals, government, academia, community/religious organizations, and all other relevant breast cancer stakeholders worldwide to take action on three priority areas for women living with metastatic breast cancer (MBC):

• Improve access to tailored information, resources and support for women with MBC
• Heighten attention to the MBC community-create a unified voice and platform that speaks to their unique needs
• Increase understanding of and access to clinical trials.

“While there is no cure for MBC, women are living longer with metastatic disease than ever before, due in part to recent advances in treatment and supportive care,” said Dr. Marisa Weiss, Founder and President of Breastcancer.org, leading breast cancer oncologist and member of the MBC Advocacy Working Group. “It is now more critical than ever to address the complex emotional and medical needs of women dealing with metastatic disease through tailored resources and personalized support.”

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.